Drug profile · INN
sotorasib
LUMYKRAS
- US status
- approved
- Patents linked
- 0
- News articles
- 2
Quick answer
sotorasib (LUMYKRAS) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
Related news
FDA Grants Priority Review to Sotorasib for KRAS G12C NSCLC
Sotorasib receives FDA priority review for KRAS G12C non-small cell lung cancer (NSCLC), marking a pivotal step in targeted cancer treatment.
FDA Approves Breakthrough KRAS Inhibitor Lumakras for Lung Cancer
The FDA has approved Lumakras, a groundbreaking KRAS inhibitor, providing a new targeted therapy option for patients battling lung cancer.
Frequently asked questions
What is sotorasib?
sotorasib (LUMYKRAS) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for sotorasib?
LUMYKRAS is a marketed brand name for sotorasib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sotorasib?
sotorasib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.